Close this search box.

Company Name: Retrophin, Inc.

Retrophin, Inc. is a biopharmaceutical company. The company is engaged in developing, acquiring and commercializing treatments for catastrophic, rare or serious diseases. The company’s marketed products and developmental pipeline include:

  • Chenodal: Marketed treatment for gallstones
  • Thiola: Marketed treatment for cystinuria
  • Cholbam: Marketed treatment for bile acid synthesis disorders (due to single enzyme defects) and peroxisomal disorders
  • Developmental pipeline: Includes product candidates for focal segmental glomerulosclerosis (FSGS) and pantothenate kinase-associated neurodegeneration (PKAN)

Ticker Symbol: RTRX (NASDAQ)

Company Website:

Social Media:

Retrophin LinkedIn

Retrophin Twitter

Headquarters: San Diego, CA